Abstract: Objective： To systematically assess the clinical efficacy and toxic reaction of different chemotherapy regimens for recurrent epithelial ovarian cancer. Methods：The literature spublished between January 1，1995 and December 31，2011 in PubMed，Embase，Medline，Cochrane Library，EBMR，CBM，CJFD，and CNKI were searched. The RCT were searched which about the effect of different chemotherapy regimens on the progress free survival（PFS），overall survival（OS），the number of responses，complete responses，grade 3-4 hematologic toxicity reaction，grade 3-4 nonhematologic toxicity reaction for recurrent epithelial ovarian cancer. The literatures were screened according to the inclusive and exclusive criteria by two reviewers independently，then the RevMan 5.1 software was used for meta-analyses. Results：14 RCT（including 7 for platinum-sensitive and 7 for platinum-resistance） were included. Meta analysis showed that carboplatin-based chemotherapy was a favorable factor for OS（OR=0.50，95%CI：0.32-0.78，P=0.002） and responses rate（OR=1.87，95%CI：1.38-2.55，P＜0.000 1） in platinum-sensitive patients，but it was not a favorable factor for PFS（OR=1.19，95%CI：0.60-2.33，P=0.62）and can increase the risk of leukocyte reduction. Two studies show that topotecan can improve OS in platinum-resistance patients. Gemcitabine was not a favorable factor for responses rate（OR=1.29，95%CI：0.67-2.46，P=0.45） and can increase the risk of neutropenia reduction （OR=2.97，95%CI：1.70-5.17，P=0.000 1） compared with PLD in platinum-resistance patients. Conclusions：Carboplatin-based chemotherapy can be improve OS and responses rate in platinum-sensitive patients，It should pay attention to monitor hematologic toxicity reaction during chemotherapies. Topotecan can improve OS but it was not a favorable factor for PFS in platinum-resistance patients. It can be used as research direction in the future for platinum-resistance patients. It is not a high methodological quality studies in this meta analysis and still need more rigorous quality RCT study to confirmed.

Key words: Ovarian neoplasms, Antineoplastic combined chemotherapy protocols, Meta-analysis, Treatment outcome